GC
VRTX icon

Gratus Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Gratus Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-14,765
Closed -$1.86M – 94
2015
Q4 		$1.86M Buy
+14,765
New +$1.78M 0.42% 46

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gratus Capital's VRTX Position: Q1 2016 in Review

Gratus Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 14,765 shares — an estimated $1.86M sold.

Gratus Capital first reported a position in VRTX in Q4 2015 and held it in 1 quarter. The position peaked at $1.86M in Q4 2015. 502 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

  • Gratus Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Gratus Capital sold 14,765 Vertex Pharmaceuticals shares in Q1 2016, an estimated $1.86M.
  • Gratus Capital first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Gratus Capital's Vertex Pharmaceuticals position peaked at $1.86M in Q4 2015.
  • 502 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Gratus Capital's 13F filing for Q1 2016, filed 11 May 2016.